Allergen Immunotherapy (AIT)
Treatment for Allergic Rhinitis
Typical Dosage: Allergen-specific, gradually increasing doses
Effectiveness
90%
Safety Score
60%
Clinical Trials
19
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Allergen-specific, gradually increasing doses
Time to Effect
3-6 months for initial effect, 1-3 years for maximal benefit
Treatment Duration
3-5 years
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
30(Treat 30 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,500
Monitoring:$900
Side Effect Mgmt:$100
Total Annual:$2,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$3,205.13
Cost per Remission
$6,250
Comparison vs Intranasal Corticosteroids
Cost Difference
+$2,285/year
More expensive
QALY Difference
+0.08 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Risk Assessment
Requires Monitoring
YesNeeds lab work/checkups
Allergen Immunotherapy (AIT) Outcomes
for Allergic Rhinitis
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+78%
Remission Rate
+40%
Common Side Effects
Local injection site reactions
+60%
Local oral reactions (SLIT)
+40%
Systemic reactions (SCIT)
+3%
Sources:
Active Clinical Trials
2 active trials recruiting for Allergen Immunotherapy (AIT) in Allergic Rhinitis
Identification of B Regulatory Cells by Flow Cytometry
NCT06876506NOT YET RECRUITING
80 participants
OBSERVATIONAL
Hull, United Kingdom
Started: Feb 1, 2026
Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab
NCT07013123NOT YET RECRUITINGPHASE3
38 participants
INTERVENTIONAL
Started: Jul 15, 2025
Completed Clinical Trials
12 completed trials for Allergen Immunotherapy (AIT) in Allergic Rhinitis
Comparison of Innate Immune Responses Induced by Allergy Immunotherapy (AIT) With Different Adjuvants
NCT04104828COMPLETED
24 participants
OBSERVATIONAL
Zurich, Switzerland
Started: Nov 5, 2019
Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study
NCT02005627COMPLETEDPHASE2
46 participants
INTERVENTIONAL
London, United Kingdom
Started: Sep 1, 2013
Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma
NCT03821077COMPLETED
122 participants
OBSERVATIONAL
Cornellà de Llobregat, Spain +9 more
Started: Aug 30, 2018
Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass
NCT04296474COMPLETEDPHASE1, PHASE2
34 participants
INTERVENTIONAL
Lund, Sweden +2 more
Started: May 15, 2018
Safety and Efficacy of Sublingual Immunotherapy for Allergic Rhinitis Due to Artemisia Annua
NCT03990272COMPLETEDPHASE3
702 participants
INTERVENTIONAL
Beijing, China +12 more
Started: Mar 20, 2017
Evaluation of the Benefits of Sublingual AIT (PRACTIS)
NCT06574061COMPLETED
1.64K participants
OBSERVATIONAL
Antony, France
Started: Aug 29, 2018
Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)
NCT01549340COMPLETED
8.79K participants
OBSERVATIONAL
Started: Nov 1, 2011
Immunological Comparison of AIT and SCIT Immunotherapy Against Grass Pollen
NCT01889875COMPLETEDNA
40 participants
INTERVENTIONAL
Copenhagen NV, Denmark
Started: Nov 1, 2010
the Relationship Between Allergic Rhinitis and the Risk of Symptom in Patients With Mild COVID-19
NCT05753241COMPLETED
1.1K participants
OBSERVATIONAL
Chengdu, China
Started: Nov 10, 2022
House Dust Mite Injection Immunotherapy in Elderly Patients.
NCT03209245COMPLETEDPHASE3
58 participants
INTERVENTIONAL
Started: Apr 10, 2014
Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy.
NCT06448585COMPLETEDPHASE4
60 participants
INTERVENTIONAL
Don Benito, Spain
Started: May 29, 2024
N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France
NCT03746860COMPLETED
1.51K participants
OBSERVATIONAL
Montpellier, France
Started: May 9, 2018